Summary
- Eli
Lilly has raised its full-year adjusted profit forecast to $21.75 to $23
per share, up from the previous range of $20.78 to $22.28. - The
company’s weight-loss drug, Zepbound, along with its diabetes treatment
counterpart Mounjaro, is driving strong sales growth. - Zepbound
generated $1.24 billion in revenue in the second quarter of 2024,
achieving blockbuster status within months of launch. - Mounjaro
sales reached $3.1 billion in Q2 2024, more than tripling compared to the
same period last year. - Eli
Lilly is expected to overtake Danish rival Novo Nordisk in the GLP-1
market by 2025, fueled by demand for its dual-action therapies. - Analysts
forecast continued strong growth for Eli Lilly’s weight-loss and diabetes
drugs, with sales of Zepbound and Mounjaro expected to soar further in
2025 and 2026. - Lilly
is also pioneering next-generation oral obesity medications, with
promising Phase 3 trial results reported for orforglipron. - Despite
optimistic sales forecasts, Eli Lilly’s stock experienced some volatility
due to concerns about competition and market dynamics. - Novo
Nordisk has lowered its sales guidance amid slower obesity drug uptake and
competition from compounded semaglutide alternatives. - Eli
Lilly has made significant investments in manufacturing capacity to meet
increasing demand for its treatments.
Eli Lilly, headquartered in Indianapolis, Indiana, has significantly raised its full-year profit forecast driven by the strong sales performance of its weight-loss drugs, Zepbound and Mounjaro. These blockbuster therapies have not only positioned Eli Lilly as a leading player in the obesity and diabetes treatment market but also sparked optimism about the company’s future growth. The company’s substantial investments in manufacturing facilities within Indiana and North Carolina further underscore its commitment to meeting the increasing demand for these treatments across the United States and globally. This strategic positioning consolidates Eli Lilly’s role at the forefront of innovative pharmaceutical development in the U.S. biotech hub.
What Financial Forecast Changes Did Eli Lilly Announce?
As reported by multiple sources including Reuters and CNBC,
Eli Lilly raised its full-year adjusted earnings forecast for 2025 to
a range of $21.75 to $23 per share, above its earlier guidance of $20.78 to
$22.28 per share. This upward revision reflects the strong market reception and
sales performance of its weight-loss drug Zepbound and diabetes therapy
Mounjaro.
The company also lifted its revenue guidance for 2024 to
between $45.4 billion and $46.6 billion, up from a prior range of $42.4 billion
to $43.6 billion, signaling robust financial momentum fueled by these
blockbuster drugs.
How Are Zepbound and Mounjaro Driving Lilly’s Growth?
Zepbound, Eli Lilly’s weight-loss injection launched in
November 2023, earned $1.24 billion in Q2 2024 alone, more than doubling its
first-quarter revenue of $517 million and reaching blockbuster status within
its first calendar year on the market. Mounjaro, which shares the same active
ingredient as Zepbound, generated $3.1 billion in Q2 sales, a significant leap
from $979.7 million recorded in the same quarter the previous year.
Sara Reci, managing analyst at GlobalData, noted to
Pharmaceutical Technology that despite competition from Novo Nordisk’s Wegovy,
Eli Lilly is rapidly closing the market gap thanks to these therapies.
Further supporting this growth narrative, UBS analyst Trung
Huynh indicated that Eli Lilly captures about two-thirds of new patients
beginning treatment with Zepbound, bolstered by recent study results showing
better weight-loss outcomes with Zepbound compared to Wegovy.
What Is the Competitive Landscape Between Eli Lilly and Novo
Nordisk?
The weight-loss and diabetes drug market, dominated by GLP-1
medications, has been a fierce competition primarily between Lilly’s Mounjaro
and Zepbound and Novo Nordisk’s Wegovy and Ozempic. According to Visible Alpha
estimates reported by S&P Global, Eli Lilly is on track to surpass Novo
Nordisk in this sector by 2025 due to soaring demand for its dual-action drugs.
Novo Nordisk, the pioneer with earlier approvals for Wegovy
and Ozempic, has faced challenges such as supply bottlenecks, increased usage
of compounded semaglutide, and trial disappointments for next-gen drugs like
CagriSema. These issues have led to lowered sales growth forecasts and a
substantial drop in its stock price.
By contrast, Lilly’s growth trajectory appears stronger,
with analysts predicting Mounjaro sales to increase by 60% year-over-year to
$18.4 billion in 2025, and Zepbound sales expected to more than double from
$4.9 billion in 2024 to $12.5 billion in 2025, growing further in subsequent
years.
How Is Lilly Innovating With New Weight-Loss Treatments?
Eli Lilly is not resting on current successes. The company
is pioneering next-generation oral weight-loss medications, exemplified by the
promising Phase 3 clinical trial results of orforglipron, an oral GLP-1
treatment. This medication demonstrated statistically significant weight-loss
efficacy and a safety profile comparable to injectable GLP-1 drugs.
The company plans to seek FDA approval for orforglipron by
2026, expanding its product portfolio and reinforcing its leadership in obesity
treatment.
Ken Custer, Lilly’s executive vice president overseeing
cardiometabolic health, highlighted the company’s strategy to dominate the
anti-obesity market by 2030, with Lilly’s drugs expected to capture nearly 50%
of the $95 billion market by then.
What Are the Market Reactions and Stock Performance?
Following the announcement of strong sales and higher profit
guidance, Eli Lilly’s shares initially jumped by nearly 12% but experienced
some midday volatility in August 2024. Earlier in 2025, shares surged 16% after
promising oral weight-loss drug trial results were reported.
However, concerns linger among investors about potential
pricing pressures if Novo Nordisk aggressively cuts prices or if the obesity
drug market growth slows unexpectedly. Despite these concerns, Lilly’s market
value had surpassed $700 billion, making it the world’s most valuable
pharmaceutical company as of mid-2024.
What Investments Is Eli Lilly Making to Meet Demand?
Eli Lilly has aggressively invested in expanding
manufacturing capabilities to keep pace with the high demand for Mounjaro and
Zepbound. In 2024, the company committed an additional $5.3 billion to a
production facility in Indiana dedicated to tirzepatide (the active ingredient
in both drugs) and planned the opening of a new plant in North Carolina by
year-end.
Additionally, Lilly started offering higher-dose versions of
Zepbound directly to consumers via its website, broadening accessibility and
convenience for patients.
Eli Lilly’s combination of robust sales, strategic
investments, innovative drug development, and market positioning is reshaping
the landscape of obesity and diabetes treatment, positioning it to overtake
established rivals by the mid-2020s and dominate the market for years to come.
The company’s strong forecast revisions and promising pipeline underscore the
growing importance and financial potential of weight-loss therapies in the
global pharmaceutical industry.
